Kazazian Asset Management LLC Sells 53,758 Shares of Indivior PLC (NASDAQ:INDV)

Key Points

• Kazazian Asset Management LLC reduced its holdings in Indivior PLC by 40.4% to 79,425 shares, which are valued at approximately $757,000, making it the firm's 26th largest position.
• Institutional investors currently hold about 60.33% of Indivior's stock, with several firms, including Deerfield Management and Newtyn Management, significantly increasing their positions in the fourth quarter.
• Indivior recently reported earnings of $0.51 per share, surpassing analyst expectations, and currently has a consensus rating of "Buy" with a target price of $17.75.

Kazazian Asset Management LLC lessened its holdings in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 40.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 79,425 shares of the company's stock after selling 53,758 shares during the quarter. Indivior makes up approximately 0.6% of Kazazian Asset Management LLC's portfolio, making the stock its 26th largest holding. Kazazian Asset Management LLC owned 0.06% of Indivior worth $757,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Deerfield Management Company L.P. Series C grew its holdings in Indivior by 74.4% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock valued at $110,418,000 after buying an additional 3,790,518 shares during the last quarter. Newtyn Management LLC raised its stake in shares of Indivior by 62.0% in the 4th quarter. Newtyn Management LLC now owns 1,406,531 shares of the company's stock valued at $17,483,000 after buying an additional 538,426 shares in the last quarter. Millennium Management LLC raised its position in Indivior by 36.9% in the fourth quarter. Millennium Management LLC now owns 1,233,006 shares of the company's stock worth $15,326,000 after purchasing an additional 332,180 shares in the last quarter. Ardsley Advisory Partners LP raised its holdings in shares of Indivior by 11.0% in the 4th quarter. Ardsley Advisory Partners LP now owns 1,200,000 shares of the company's stock worth $14,916,000 after buying an additional 119,050 shares in the last quarter. Finally, CenterBook Partners LP grew its position in Indivior by 105.5% in the fourth quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock valued at $14,268,000 after acquiring an additional 589,158 shares during the period. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Price Performance

Shares of NASDAQ INDV traded up $0.20 during midday trading on Wednesday, reaching $22.00. The company's stock had a trading volume of 2,371,194 shares, compared to its average volume of 1,763,892. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $22.06. The stock has a 50 day simple moving average of $15.25 and a 200-day simple moving average of $12.03.

Indivior (NASDAQ:INDV - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.26 by $0.25. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. The business had revenue of $302.00 million for the quarter, compared to the consensus estimate of $239.43 million. Equities research analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

INDV has been the subject of several research analyst reports. Wall Street Zen upgraded Indivior from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. HC Wainwright began coverage on Indivior in a report on Wednesday. They set a "buy" rating and a $27.00 price objective for the company. Jefferies Financial Group started coverage on shares of Indivior in a research note on Tuesday, July 22nd. They issued a "buy" rating and a $20.00 price objective on the stock. Finally, Craig Hallum upped their price objective on Indivior from $15.00 to $22.00 and gave the company a "buy" rating in a report on Monday, June 30th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $19.60.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.